Brown Advisory’s Takeda Pharmaceutical TAK Stock Holding History

Brown Advisory’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-10,737	Closed	-$196K	–	1126
2021 Q1	$196K	Buy	10,737 +213	+2%	+$3.83K	﹤0.01%	1037
2020 Q4	$191K	Buy	+10,524	New	+$185K	﹤0.01%	974
2019 Q3	–	Sell	-50,445	Closed	-$893K	–	1038
2019 Q2	$893K	Buy	50,445 +2,015	+4%	+$36.7K	﹤0.01%	651
2019 Q1	$986K	Buy	+48,430	New	+$975K	﹤0.01%	811

Other funds holding TAK

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

PPA

Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return

MIP

Mondrian Investment Partners London, United Kingdom $6.69B AUM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Brown Advisory's TAK Position: Q2 2021 in Review

Brown Advisory sold out of Takeda Pharmaceutical (TAK) in Q2 2021, closing a stake of 10,737 shares — an estimated $196K sold.

Brown Advisory first reported a position in TAK in Q1 2019 and held it in 4 quarters. The position peaked at $986K in Q1 2019. 304 funds tracked by Wall St. Rank hold TAK as of Q2 2021.

Brown Advisory reported no remaining Takeda Pharmaceutical position as of Q2 2021 after selling out during the quarter.
Brown Advisory sold 10,737 Takeda Pharmaceutical shares in Q2 2021, an estimated $196K.
Brown Advisory first reported a position in Takeda Pharmaceutical in Q1 2019 and held it in 4 quarters.
Brown Advisory's Takeda Pharmaceutical position peaked at $986K in Q1 2019.
304 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2021.

Based on Brown Advisory's 13F filing for Q2 2021, filed 29 Jul 2021.